Hikma has launched its US generic rival to Vascepa (icosapent ethyl) 1g capsules after the US Court of Appeals for the Federal Circuit refused a request by Amarin to rehear a case that was decided in favor of both Hikma and Dr Reddy’s in September.
The appeals court had affirmed in September a Nevada district court ruling that Hikma and Dr Reddy’s infringed six of Amarin’s patents covering methods of treating hypertriglyceridemia, but that the patents were invalid as obvious
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?